Skip to main content
SpringerLink
Log in
Book cover

Thrombolytic Therapy for Acute Stroke pp 3–27Cite as

Mechanisms of Thrombolysis

  • Chapter

Part of the book series: Current Clinical Neurology ((CCNEU))

Abstract

The pharmacological use of plasminogen activators is associated with symptomatic improvement in patients with coronary artery thrombosis, peripheral arterial occlusions, and thrombosis of the venous system. Based on prospective angiographic studies and planned programs (1–5), thrombolysis is the only approved treatment of acute ischemic stroke (6–8) under limited circumstances. Currently, recombinant tissue plasminogen activator (rt-PA) is licensed in the United States and several other countries for the treatment of ischemic stroke within 3 h of onset (6).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. del Zoppo GJ, Ferbert A, Otis S, et al. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke: A pilot study. Stroke 1988;19:307–313.

    PubMed  Google Scholar 

  2. Mori E, Tabuchi M, Yoshida T, Yamadori A. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke 1988;19:802–812.

    PubMed  CAS  Google Scholar 

  3. del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992;32:78–86.

    Article  PubMed  Google Scholar 

  4. Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992;42:976–982.

    PubMed  CAS  Google Scholar 

  5. Yamaguchi T, Hayakawa T, Kikuchi H. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis 1993;3:269–272.

    Article  Google Scholar 

  6. The National Institutes of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587.

    Article  Google Scholar 

  7. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017–1025.

    Article  PubMed  CAS  Google Scholar 

  8. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, for the Second European-Australasian acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245–1251.

    Article  PubMed  CAS  Google Scholar 

  9. Sherry S. The history and development of thrombolytic therapy. In: Thrombolytic Therapy for Peripheral Vascular Disease, Comerota AJ, ed. J. B. Lippincott Co: Philadelphia. 1995; pp. 67–86.

    Google Scholar 

  10. Kaplan MH. Nature and role of the lytic factor in hemolytic streptococcal fibrinolysis. Proc Soc Exp Biol Med 1944;57:40–43.

    CAS  Google Scholar 

  11. Christensen LR, MacLeod CM. A proteolytic enzyme of serum: Characterization, activation, and reaction with inhibitors. J Gen Physiol 1945;28:559–583.

    Article  CAS  PubMed  Google Scholar 

  12. Tillett WS, Sherry S. The effect in patients of streptokinase fibrinolysis (streptokinase) and streptococcal deoxyribonuclease on fibrinous, purulent and sanguineous pleural exudations. J Clin Invest 1949;28:173–190.

    PubMed  CAS  Google Scholar 

  13. Johnson AJ, Tillett WS. Lysis in rabbits of intravascular blood clots by the streptococcal fibrinolytic system (streptokinase). J Exp Med 1952;95:449–464.

    Article  PubMed  CAS  Google Scholar 

  14. Hermans J, McDonagh J. Fibrin: Structure and interactions. Semin Thromb Hemost 1982;8:11–24.

    PubMed  CAS  Google Scholar 

  15. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 1991;30:10,363–10,370.

    Article  PubMed  CAS  Google Scholar 

  16. Nossel HL. Relative proteolysis of fibrin B-beta chain by thrombin and plasmin as a determinant of thrombosis. Nature 1981;291:754–762.

    Article  Google Scholar 

  17. Alkjaersig N, Fletcher AP. Catabolism and excretion of fibrinopeptide A. Blood 1982;60:148–156.

    PubMed  CAS  Google Scholar 

  18. Majerus PW, Miletich JP, Kane WP, Hoffmann SL, Stanford N, Jackson CM. The formation of thrombin on platelet surface. In: The Regulation of Coagulation, Mann KG, Taylor FB, eds. Elsevier/North Holland: New York. 1980; pp. 215–215.

    Google Scholar 

  19. Kaplan AP. Initiation of the intrinsic coagulation and fibrinolytic pathways of man: The role of surfaces, Hageman factor, prekallikrein, high molecular weight kininogen, and factor XI. Prog Hemost Thromb 1978;4:127–175.

    PubMed  CAS  Google Scholar 

  20. Nesheim ME, Hibbard LS, Tracy PB, Bloom JW, Myrmel KH, Mann KA: Participation of factor Va in prothrombinase. In: The Regulation of Coagulation, Mann KG, Tayler FB, eds. Elsevier/North Holland: New York. 1980; pp. 145–159.

    Google Scholar 

  21. Miletich JP, Jackson CM, Majerus PW. Properties of the factor Xa binding site on human platelets. J Biol Chem 1978;253:6908–6916.

    PubMed  CAS  Google Scholar 

  22. Levin EG, Marzec U, Anderson J, Harker LA. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest 1984;74:1988–1995.

    PubMed  CAS  Google Scholar 

  23. Van Hinsbergh VWM. Regulation of the synthesis and secretion of plasminogen activators by endothelial cells. Haemostasis 1988;18:307–327.

    PubMed  Google Scholar 

  24. Liesi P, Kirkwood T, Vaheri A. Fibronectin is expressed by astrocytes cultured from embryonic and early postnatal rat brain. Exp Cell Res 1986;163:175–185.

    Article  PubMed  CAS  Google Scholar 

  25. Giles AR, Nosheim ME, Herring SW, Hoogendoorn H, Stump DC, Heldebrant CM. The fibrinolytic potential of the normal primate following the generation of thrombin in vivo. Thromb Haemost 1990;63:476–481.

    PubMed  CAS  Google Scholar 

  26. Schwartz ML, Pizzo SV, Hill RL, McKee PA. Human factor XIII from plasma and platelets. Molecular weight, subunit structures, proteolytic activation and cross-linking of fibrinogen and fibrin. J Biol Chem 1973; 248:1395–1407.

    PubMed  CAS  Google Scholar 

  27. Gaffney PJ, Whittaker AN. Fibrin cross-links and lysis rates. Thromb Res 1979;14:85–94.

    Article  PubMed  CAS  Google Scholar 

  28. Nawroth PP, Stern DM. Endothelial cells as active participants in procoagulant reactions. In: Vascular Endothelium in Hemostasis and Thrombosis, Gimbrone MA, ed. Churchill-Livingstone: Edinburgh. 1986; pp. 14–39.

    Google Scholar 

  29. Collen D, de Maeyer L. Molecular biology of human plasminogen. I. Physiocochemical properties and microheterogeneity. Thromb Diath Haemorhag 1975;34:396–402.

    CAS  Google Scholar 

  30. Levin EG, del Zoppo GJ. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels. Am J Pathol 1994;144:855–861.

    PubMed  CAS  Google Scholar 

  31. Plow EF, Felez J, Miles LA. Cellular regulation of fibrinolysis. Thromb Haemost 1991;66:132–136.

    Google Scholar 

  32. Bachmann F, Kruithof IEKO. Tissue plasminogen activator: Chemical and physiological aspects. Semin Thromb Hemost 1984;10:6–17.

    PubMed  CAS  Google Scholar 

  33. Aoki N, Harpel PC. Inhibitors of the fibrinolytic enzyme system. Semin Thromb Hemost 1984;10:24–41.

    PubMed  CAS  Google Scholar 

  34. Collen D, Lijnen HR. New approaches to thrombolytic therapy. Arteriosclerosis 1984;4:579–585.

    PubMed  CAS  Google Scholar 

  35. Verstraete M, Collen D. Thrombolytic therapy in the eighties. Blood 1986;67:1529–1541.

    PubMed  CAS  Google Scholar 

  36. Gaffrey PJ, Lane DA, Kakkar VV, Brahser M. Characterization of a soluble D-dimer-E complex in cross-linked fibrin digests. Thromb Res 1975;7:89–99.

    Article  Google Scholar 

  37. Forsgren M, Raden B, Israelsson M, Larsson K, Heden LO. Molecular cloning and characterization of a full-length cDNA clone for human plasminogen. FEBS Lett 1987;213:254–260.

    Article  PubMed  CAS  Google Scholar 

  38. Bachmann F. Molecular aspects of plasminogen, plasminogen activators and plasmin. In: Haemostasis and Thrombosis, Bloom AL, Forbes CD, Thomas DP, Tuddneham EGD, eds. Churchill Livingstone: Edinburgh. 1994; pp. 575–613.

    Google Scholar 

  39. Wallen P, Wiman B. Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen. Biochim Biophys Acta 1973;257:122–134.

    Google Scholar 

  40. Holvoet P, Lijnen HR, Collen D. A monoclonal antibody specific for lys-plasminogen. Application to the study of the activation pathways of plasminogen in vivo. J Biol Chem 1985;260:12,106–12,111.

    PubMed  CAS  Google Scholar 

  41. Thorsen S, Mullertz S, Svenson E, Kok P. Sequence of formation of molecular forms of plasminogen and plasminogen-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator. Biochem J 1984;223:179–187.

    PubMed  CAS  Google Scholar 

  42. Peterson LC, Serenson E. Effect of plasminogen and tissue-type plasminogen activator on fibrin gel structure. Fibrinolysis 1990;5:51–59.

    Article  Google Scholar 

  43. Tran-Thong C, Kruithof EKO, Atkinson J, Bachmann F. High-affinity binding sites for human glu-plasminogen unveiled by limited plasmic degradation of human fibrin. Eur J Biochem 1986;160:559–604.

    Article  Google Scholar 

  44. Miles LA, Greengard JS, Griffin JH. A comparison of the abilities of plasma kallikrein, Beta-Factor XIIa, Factor XIa and urokinase to activate plasminogen. Thromb Res 1983;29:407–417.

    Article  PubMed  CAS  Google Scholar 

  45. Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Semin Thromb Hemost 1987;13:50–68.

    PubMed  CAS  Google Scholar 

  46. Wun TC, Ossowski L, Reich E. A proenzyme of human urokinase. J Biol Chem 1982;257:7262–7276.

    PubMed  CAS  Google Scholar 

  47. Wun TC, Schleuning E, Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem 1982;257:3276–3287.

    PubMed  CAS  Google Scholar 

  48. Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986;261:3486–3489.

    PubMed  CAS  Google Scholar 

  49. Hanss M, Collen D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: Modulation by thrombin endotoxin and histamine. J Lab Clin Med 1987;109:97–104.

    PubMed  CAS  Google Scholar 

  50. Levin EG, Stern DM, Nawrath PP, et al. Specificity of the thrombin-induced release of tissue plasminogen activator from cultured human endothelial cells. Thromb Haemost 1986;56:115–119.

    PubMed  CAS  Google Scholar 

  51. Robbins KC, Summaria L, Hsieh B, Shah RJ. The peptide chains of human plasmin. J Biochem 1967; 242:2333–2342.

    CAS  Google Scholar 

  52. Robbins KC. The plasminogen-plasmin system. In: Thrombolytic Therapy for Peripheral Vascular Disease, Comerota AJ, ed. J. B. Lippincott: Philadelphia. 1995; pp. 41–65.

    Google Scholar 

  53. Wiman B, Collen D. Molecular mechanism of physiological fibrinolysis. Nature 1979;272:549–550.

    Article  Google Scholar 

  54. Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980;43:77–89.

    PubMed  CAS  Google Scholar 

  55. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982;257:2912–2919.

    PubMed  CAS  Google Scholar 

  56. Wun T-C, Capugno A. Initiation and regulation of fibrinolysis in human plasma at the plasminogen activator level. Blood 1987;69:1354–1362.

    PubMed  CAS  Google Scholar 

  57. Bloom AL, Thomas DP. Haemostasis and Thrombosis. Edinburgh, Churchill-Livingstone, 1987.

    Google Scholar 

  58. Kakkar VV, Scully MF. Thrombolytic therapy. Br Med Bull 1978;34:191–199.

    PubMed  CAS  Google Scholar 

  59. Sharma GVRK, Cella G, Parish AF, Sasahara AA. Drug therapy: Thrombolytic therapy. N Engl J Med 1982;306:1268–1276.

    Article  PubMed  CAS  Google Scholar 

  60. Verstraete M. Biochemical and clinical aspects of thrombolysis. Semin Hematol 1978;15:35–54.

    PubMed  CAS  Google Scholar 

  61. Castellino FJ. Biochemistry of human plasminogen. Semin Thromb Hemost 1984;10:18–23.

    Article  PubMed  CAS  Google Scholar 

  62. Yasaka M, Yamaguchi T, Miyashita T, Tsuchiya T. Regression of intracardiac thrombus after embolic stroke. Stroke 1990;21:1540–1544.

    PubMed  CAS  Google Scholar 

  63. Bounameaux H, de Moerloose P, Perrier A, Reber G. Plasma measurement of D-dimer as diagnostic aid in suspected venous thromboembolism: An overview. Thromb Haemost 1994;71:1–6.

    PubMed  CAS  Google Scholar 

  64. Rijken DC. Structure/function relationships of t-PA. In: Tissue Type Plasminogen Activator (t-PA):Physiological and Clinical Aspects Vol. 1, Kluft C, ed. CRC Press: Boca Raton. 1988; pp. 101–122.

    Google Scholar 

  65. Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA. Cloning and expression of human tissue-type plasminogen activator cDNA in E coli. Nature 1983;301:214–221.

    Article  PubMed  CAS  Google Scholar 

  66. Ehrlich HJ, Bang NW, Little SP, et al. Biological properties of a kringleless tissue plasminogen activator (t-PA) mutant. Fibrinolysis 1987;1:75–81.

    Article  CAS  Google Scholar 

  67. Ranby M, Bergsdorf N, Norrman B, Svenson E, Wallen P. Tissue plasminogen activator kinetics. In: Progress in Fibrinolysis Vol. VI, Davison JF, Bachmann F, Bouvier CA, Kruithof EKO, eds. Churchill-Livingstone: New York. 1982; pp. 182–182.

    Google Scholar 

  68. Gelehrter TD, Sznycer-Laszuk R. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. J Clin Invest 1986;77:165–169.

    PubMed  CAS  Google Scholar 

  69. Sakata Y, Curriden S, Lawrence D, et al. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA 1985;82:1121–1125.

    Article  PubMed  CAS  Google Scholar 

  70. Moscatelli D. Urokinase-type and tissue-type plasminogen activators have different distributions in cultured bovine capillary endothelial cells. J Cell Biochem 1986;30:19–29.

    Article  PubMed  CAS  Google Scholar 

  71. Bulens F, Nelles L, Van den Panhuyzen N, Collen D. Stimulation by retinoids of tissue-type plasminogen activator secretion in cultured human endothelial cells: Relations of structure to effect. J Cardiovasc Pharmacol 1992;19:508–514.

    Article  PubMed  CAS  Google Scholar 

  72. Thompson EA, Nelles L, Collen D. Effect of retinoic acid on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-I in human endothelial cells. Eur J Biochem 1991;201:627–632.

    Article  PubMed  CAS  Google Scholar 

  73. Saksela O, Moscatelli D, Rifkin DB. The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells and decreases antiactivator activity. J Cell Biol 1987;105:957–963.

    Article  PubMed  CAS  Google Scholar 

  74. Levin EG, Marotti KR, Santell L. Protein kinase C and the stimulation of tissue plasminogen activator release from human endothelial cells. Dependence on the elevation of messenger RNA. J Biol Chem 1989;264:16,030–16,036.

    PubMed  CAS  Google Scholar 

  75. Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1985;66:835–839.

    PubMed  CAS  Google Scholar 

  76. Brommer EJP. Clinical relevance of t-PA levels of fibrinolytic assays. In: Tissue-Type Plasminogen Activator (t-PA): Physiological and Clinical Aspects Part 2, Kluft C, ed. CRC Press: Boca Raton. 1988; pp. 89–89.

    Google Scholar 

  77. Agnelli G. The pharmacological basis of thrombmolytic therapy. In: Thrombolysis Yearbook 1995, Agnelli G, ed. Excerpta Medica: Amsterdam. 1995; pp. 31–61.

    Google Scholar 

  78. Verstraete M, Bounameaux H, de Cock F, Van de Loerf F, Collen D. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther 1986;235:506–512.

    Google Scholar 

  79. Krystosek A, Seeds NW. Normal and malignant cells, including neurons, deposit plasminogen activator on growth substrata. Exp Cell Res 1986;166:31–46.

    Article  PubMed  CAS  Google Scholar 

  80. Pittman RN. Release of plasminogen activator and a calcium-dependent metalloprotease from cultured sympathetic and sensory neurons. Dev Biol 1985;110:91–101.

    Article  PubMed  CAS  Google Scholar 

  81. Vincent VA, Lowik CW, Verheijen JH, de Bart AC, Tilders FJ, Van Dam AM. Role of astrocyte-derived tissue-type plasminogen activator in the regulation of endotoxin-stimulated nitric oxide production by microglial cells. GLIA 1998;22:130–137.

    Article  PubMed  CAS  Google Scholar 

  82. Toshniwal PK, Firestone SL, Barlow GH, Tiku ML. Characterization of astrocyte plasminogen activator. J Neurol Sci 1987;80:277–287.

    Article  PubMed  CAS  Google Scholar 

  83. Tsirka SE, Rogove AD, Bugge TH, Degen JL, Strickland S. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 1997;17:543–552.

    PubMed  CAS  Google Scholar 

  84. Masos T, Miskin R. Localization of urokinase-type plasminogen activator mRNA in the adult mouse brain. Brain Res Mol Brain Res 1996;35:139–148.

    Article  PubMed  CAS  Google Scholar 

  85. Tranque P, Naftolin F, Robbins R. Differential regulation of astrocyte plasminogen activators by insulin-like growth factor-I and epidermal growth factor. Endocrinology 1994;134:2606–2613.

    Article  PubMed  CAS  Google Scholar 

  86. Nakajima K, Tsuzaki N, Shimojo M, Hamanoue M, Kohsaka S. Microglia isolated from rat brain secrete a urokinase-type plasminogen activator. Brain Res 1992;577:285–292.

    Article  PubMed  CAS  Google Scholar 

  87. Lijnen HR, Zamarron C, Blaber M, Winkler ME, Collen D. Activation of plasminogen by pro-urokinase. I. Mechanism. J Biol Chem 1986;261:1253–1258.

    PubMed  CAS  Google Scholar 

  88. Peterson LC, Lund LR, Nielsen LS, Dano K, Shriver L. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem 1988;263:11,189–11,195.

    Google Scholar 

  89. Gunzler WA, Steffens GJ, Otting F, Buse G, Flohe L. Structural relationship between human high and low molecular mass urokinase. Hoppe Seylers Z Physiol Chem 1982;563:133–141.

    Google Scholar 

  90. White FW, Barlow GH, Mozen MM. The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry 1966;5:2160–2169.

    Article  PubMed  CAS  Google Scholar 

  91. Fletcher AP, Alkjaersig N, Sherry S, Genton E, Hirsh J, Bachmann F. The development of urokinase as a thrombolytic agent. Maintenance of a sustained thrombolytic state in man by its intravenous infusion. J Lab Clin Med 1965;65:713–731.

    PubMed  CAS  Google Scholar 

  92. Stump DC, Mann KH. Mechanisms of thrombus formation and lysis. Ann Emerg Med 1988;17:1138–1147.

    Article  PubMed  CAS  Google Scholar 

  93. Davies MC, Englert ME, De Rezo EC. Interaction of streptokinase and human plasminogen observed in the ultracentrifuge under a variety of experimental conditions. J Biol Chem 1964;239(8):2651–2656.

    PubMed  CAS  Google Scholar 

  94. Reddy KN, Marcus B. Mechanisms of activation of human plasminogen by streptokinase. J Biol Chem 1972;246:1683–1691.

    Google Scholar 

  95. Fletcher AP, Alkjaersig N, Sherry S. The clearance of heterologous proteins from the circulation of normal and immunized man. J Clin Invest 1958;37(9):1306–1315.

    PubMed  CAS  Google Scholar 

  96. Standing R, Fears R, Ferres H. The protective effect of acylation on the stability of APSAC (Eminase) in human plasma. Fibrinolysis 1988;2:157.

    Article  Google Scholar 

  97. Ferres H. Preclinical pharmacological evaluation of Eminase (APSAC). Drugs 1987;33(Suppl 3): 33–50.

    PubMed  CAS  Google Scholar 

  98. Lignen HR, de Cock F, Matsuo O, Collen D. Comparative fibrinolytic and fibrinogenolytic properties of staphylokinase and streptokinase in plasma of different species in vitro. Fibrinolysis 1992;6:33–37.

    Article  Google Scholar 

  99. Collen D. Staphlyokinase: a potent, uniquely fibrin-selective thrombolytic agent. Nature Medicine 1998;4(3):279–282.

    Article  PubMed  CAS  Google Scholar 

  100. Jespers L, Vanwetswinkel S, Lijnen HR, Van Herzeele N, Van Hoef B, Demarsin E, et al. Structural and functional basis of plasminogen activation by staphylokinase. Thromb Haemost 1999;81(4):479–484.

    PubMed  CAS  Google Scholar 

  101. Lijnen HR, Van Hoef B, Matsuo O, Collen D. On the molecular, interactions between plasminogen-staphylokinase, α2-antiplasmin and fibrin. Biochim Biophys Acta 1992;1118:144–148.

    PubMed  CAS  Google Scholar 

  102. Witt W, Maass B, Baldus B, Hildebrand M, Donner P, Schleuning WD. Coronary thrombosis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. Circulation 1994;90:421–426.

    PubMed  CAS  Google Scholar 

  103. Bergum PW, Gardell SJ. Vampire bat salivary plasminogen activator exhibits a strict and fastidious requirement for polymeric fibrin as its cofactor, unlike human tissue-type plasminogen activator. A kinetic analysis. J Biol Chem 1992;267:17,726–17,731.

    PubMed  CAS  Google Scholar 

  104. Hare TR, Gardell SJ. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation. Thromb Haemost 1992;68:165–169.

    PubMed  CAS  Google Scholar 

  105. Witt W, Baldus B, Bringmann P, Cashion L, Donner P, Schleuning WD. Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats. Blood 1992; 79:1213–1217.

    PubMed  CAS  Google Scholar 

  106. Mellot MJ, Stabilito II, Holahan MA, et al. Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. Arterioscler Thromb 1992;12:212–221.

    Google Scholar 

  107. Gardell SJ, Ramjit DR, Stabilito II, Fujita T, Lynch JJ, Cuca GC, et al. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 1991;84:244–253.

    PubMed  CAS  Google Scholar 

  108. Lijnen HR, Collen D. Development of new fibrinolytic agents. In: Haemostasis and Thrombosis, Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Churchill-Livingstone: Edinburgh. 1994; pp. 625–637.

    Google Scholar 

  109. Van de Werf F. New thrombolytic strategies. Aust N Z J Med 1993;23:763–765.

    PubMed  Google Scholar 

  110. Barnathan ES, Kuo A, Van der Keyl H, McCrae KR, Larsen GR, Cines DB. Tissue-type plasminogen activator binding to human endothelial cells. J Biol Chem 1988;263:7792–7799.

    PubMed  CAS  Google Scholar 

  111. Smalling RW. Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator. Eur Heart J 1997;18(F):F11–F16.

    PubMed  CAS  Google Scholar 

  112. Benedict CR, Refino CJ, Keyt BA, et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995;92(10):3032–3040.

    PubMed  CAS  Google Scholar 

  113. Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, et al. TNKtissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997;95(2):351–356.

    PubMed  CAS  Google Scholar 

  114. Cannon CP, Gibson CM, McCabe CH, Adgey AA, Schweiger MJ, Sequeira RF, et al. TNKtissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 1998;98(25):2805–2814.

    PubMed  CAS  Google Scholar 

  115. Van de Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH, Berioli S, et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J 1999;137(5):786–791.

    Article  PubMed  Google Scholar 

  116. Gibson CM, Cannon CP, Murphy SA, et al. Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators. Am J Cardiol 1999;84(9):976–980.

    Article  PubMed  CAS  Google Scholar 

  117. Modi NB, Eppler S, Breed J, Cannon CP, Braunwald E, Love TW. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. Thromb Haemost 1998; 79(1):134–139.

    PubMed  CAS  Google Scholar 

  118. Pierard L, Jacobs P, Gheysen D, Hoylaerts M, Andre B, Topisirovic L, et al. Mutant and chimeric recombinant plasminogen activators. J Biol Chem 1987;262:11,771–11,778.

    PubMed  CAS  Google Scholar 

  119. Runge MS, Bode C, Matsueda GR, Haber E. Antibody-enhanced thrombolysis: Targeting of tissue plasminogen activator in vivo. Proc Natl Acad Sci USA 1987;84:7659–7662.

    Article  PubMed  CAS  Google Scholar 

  120. Bode C, Meinhardt G, Runge MS, et al. Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation. Circulation 1991;84:805–813.

    PubMed  CAS  Google Scholar 

  121. Jones RD, Donaldson IM, Parkin PJ. Impairment and recovery of ipsilateral sensory-motor function following unilateral cerebral infarction. Brain 1989;112:113–132.

    Article  PubMed  Google Scholar 

  122. Kasper W, Meinertz T, Hohnloser S, Engler H, Hasler C, Rossler W, et al. Coronary thrombolysis in man with prourokinase: Improved efficacy with low dose urokinase. Klin Wochenschr 1988;66:109–114.

    PubMed  Google Scholar 

  123. Bachmann F. Fibrinolysis. In: Thrombosis and Haemostasis, Verstraete M, Vermylen J, Lijnen HR, Arnout J, eds. Leuven, ISTH/University of Leuven Press: 1987; pp. 227–265.

    Google Scholar 

  124. Kluft C, Los N. Demonstration of two forms of α2-antiplasmin in plasma by modified crossed immunoelectrophoresis. Thromb Res 1981;21:65–71.

    Article  PubMed  CAS  Google Scholar 

  125. Winman B, Nilsson T, Cedergren B. Studies on a form of α2-antiplasmin in plasma which does not interact with the lysine-binding sites in plasminogen. Thromb Res 1982; 28:193–200.

    Article  Google Scholar 

  126. Aoki N, Harpel P. Inhibitors of the fibrinolytic enzyme system. Semin Hemostat Thromb 1984;10:24–39.

    CAS  Google Scholar 

  127. Philips M, Juul AG, Thorsen S. Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochim Biophys Acta 1984;802:99–110.

    PubMed  CAS  Google Scholar 

  128. Loskutoff DJ, van Mourik JA, Erickson LA, Lawrence DA. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 1983;80:2956–2960.

    Article  PubMed  CAS  Google Scholar 

  129. Thorsen S, Philips M, Selmer J, Lecander I, Astedt B. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2. Eur J Biochem 1988; 175:33–39.

    Article  PubMed  CAS  Google Scholar 

  130. Wilhelm OG, Jaskunas SR, Vlahos CJ, Bang NU. Functional properties of the recombinant kringle-2 domain of tissue plasminogen activator produced in Escherichia coli. J Biol Chem 1990;265:14,606–14,611.

    PubMed  CAS  Google Scholar 

  131. Juhan-Vague I, Moerman B, de Cock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33:523–530.

    Article  PubMed  CAS  Google Scholar 

  132. Kluft C, Verheihen J-H, Jie AFH, et al. The postoperative fibrinolytic shutdown: A rapidly reverting acute-phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest 1985;45:605–610.

    Article  PubMed  CAS  Google Scholar 

  133. Schleuning W-D, Medcalf RL, Hession C, Rothenb ÿhler R, Shaw A, Kruithof EKO. Plasminogen activator inhibitor 2: Regulation of gene transcription during phorbol estermediated differentiation of U-937 human histiocytic lymphoma cells. Mol Cell Biol 1987;7:4564–4567.

    PubMed  CAS  Google Scholar 

  134. Kruithof EKO, Tran-Thang C, Gudinchet A, et al. Fibrinolysis in pregnancy: A study of plasminogen activator inhibitors. Blood 1987;69:460–466.

    PubMed  CAS  Google Scholar 

  135. Bonnar J, Daly L, Sheppard BL. Changes in the fibrinolytic system during pregnancy. Semin Thromb Hemost 1990;16:221–229.

    PubMed  CAS  Google Scholar 

  136. Stump D, Thienpoint M, Collen D. Purification and characterization of a novel inhibitor of urokinase from human urine: Quantitation and preliminary characterization in plasma. J Biol Chem 1986;261:12,759–12,766.

    PubMed  CAS  Google Scholar 

  137. Heeb MJ, Espana F, Geiger M, Collen D, Stump D, Griffin JH. Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3. J Biol Chem 1987;262:15,813–15,816.

    PubMed  CAS  Google Scholar 

  138. Marder VJ, Sherry S. Thrombolytic therapy. Current status. N Engl J Med 1988;388:1512–1520.

    Article  Google Scholar 

  139. Gimple LW, Gold HK, Leinbach RC, et al. Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue plasminogen activator. Circulation 1989;80:581–588.

    PubMed  CAS  Google Scholar 

  140. Agnelli G, Buchanan MR, Fernandez F, et al. A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits. Circulation 1985;72:178–182.

    PubMed  CAS  Google Scholar 

  141. Marder VJ, Shortell CK, Fitzpatrick PG, Kim C, Oxley D. An animal model of fibrinolytic bleeding based on the rebleed phenomenon: Application to a study of vulnerability of hemostatic plugs of different age. Thromb Res 1992;67(1):31–40.

    Article  PubMed  CAS  Google Scholar 

  142. Loscalzo J, Vaughan DB. Tissue plasminogen activator promotes platelet disaggregation in plasma. J Clin Invest 1987;79:1749–1755.

    PubMed  CAS  Google Scholar 

  143. Chen LY, Muhta JL. Lys-and glu-plasminogen potentiate the inhibitory effect of recombinant tissue plasminogen activator on human platelet aggregation. Thromb Res 1994;74:555–563.

    Article  PubMed  CAS  Google Scholar 

  144. NIH Consensus Conference. Thrombolytic therapy in treatment. Br Med J 1980;280:1585–1587.

    Google Scholar 

  145. Danglet G, Vinson D, Chapeville F. Qualitative and quantitative distribution of plasminogen activators in organs from healthy adult mice. FEBS Lett 1986;194:96–100.

    Article  Google Scholar 

  146. Matsuo O, Okada K, Fukao H, Suzuki A, Ueshima S. Cerebral plasminogen activator activity in spontaneously hypertensive stroke-prone rats. Stroke 1992;23:995–999.

    PubMed  CAS  Google Scholar 

  147. Dent MA, Sumi Y, Morris RJ, Seeley PJ. Urokinase-type plasminogen activator expression by neurons and oligodendrocytes during process outgrowth in developing rat brain. Eur J Neurosci 1993;5:633–647.

    Article  PubMed  CAS  Google Scholar 

  148. Sappino A-P, Madani R, Huarte J, et al. Extracellular proteolysis in the adult murine brain. J Clin Invest 1993;92:679–685.

    Article  PubMed  CAS  Google Scholar 

  149. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (t-PA) increases neuronal damage after focal cerebral ischemia in wild-type and t-PA-deficient mice. Nature Medicine 1998;4:228–231.

    Article  PubMed  CAS  Google Scholar 

  150. del Zoppo GJ. t-PA: A neuron buster, too? (editorial). Nature Medicine 1998;4:148–150.

    Article  PubMed  Google Scholar 

  151. Tsirka SE, Rogove AD, Strickland S. Neuronal cell death and tPA. Nature 1996;384:123–124.

    Article  PubMed  CAS  Google Scholar 

  152. Tsirka SE, Gualandris A, Amaral DG, Strickland S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995;377:340–344.

    Article  PubMed  CAS  Google Scholar 

  153. del Zoppo GJ. tPA: A neuron buster, too?. Nature Medicine 1998;4:148–149.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA

    Gregory J. del Zoppo MD & Naohisa Hosomi MD

Authors
  1. Gregory J. del Zoppo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naohisa Hosomi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. USCD Stroke Center, University of California, San Diego

    Patrick D. Lyden MD

  2. Veteran’s Affairs Medical Center, San Diego, CA

    Patrick D. Lyden MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

del Zoppo, G.J., Hosomi, N. (2005). Mechanisms of Thrombolysis. In: Lyden, P.D. (eds) Thrombolytic Therapy for Acute Stroke. Current Clinical Neurology. Humana Press. https://doi.org/10.1385/1-59259-933-8:3

Download citation

  • DOI: https://doi.org/10.1385/1-59259-933-8:3

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-398-5

  • Online ISBN: 978-1-59259-933-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation